---
layout: post
title: New Drug Approvals 2012 - Pt. XV - Carfilzomib (KyorolisTM )
date: '2012-07-22T10:21:00.000+01:00'
author: Bissan Al-Lazikani
tags:
- Peptide Drugs
- 2012 New Drugs
modified_time: '2013-01-02T09:43:38.851Z'
thumbnail: http://4.bp.blogspot.com/-lmPUtdXw9lU/UOQBRPNxs0I/AAAAAAAACls/UB6UL_uo7lI/s72-c/ONYX-Pharma-Carfilzomib-Kyprolis.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-5094292218578746851
blogger_orig_url: http://chembl.blogspot.com/2012/07/new-drug-approvals-2012-pt-xv.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-lmPUtdXw9lU/UOQBRPNxs0I/AAAAAAAACls/UB6UL_uo7lI/s1600/ONYX-Pharma-Carfilzomib-Kyprolis.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="141" src="http://4.bp.blogspot.com/-lmPUtdXw9lU/UOQBRPNxs0I/AAAAAAAACls/UB6UL_uo7lI/s320/ONYX-Pharma-Carfilzomib-Kyprolis.jpg" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<center>
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,1,0,0" width="400" /><br /><br />
<b>
ATC Code: L01XX</b><br /><b>
Wikipedia: </b><a href="http://en.wikipedia.org/wiki/Carfilzomib" style="font-weight: bold;">Carfilzomib</a></center>
On July 20th 2012 the FDA approved Carfilzomib (Kyorolis<sup>TM</sup>) for the treatment of patients with <a href="http://en.wikipedia.org/wiki/Multiple_myeloma">multiple myeloma</a> who have received prior therapies including bortezomib and an immunomodulatory therapy, and who have demonstrated disease progression within 60 days of completion of the previous therapy. Multiple myeloma is a cancer of the Plasma Cells and usually in the bone marrow. Five year survival is about 40% <a href="http://info.cancerresearchuk.org/cancerstats/types/myeloma/uk-multiple-myeloma-statistics">in the UK</a> and <a href="http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/multiple-myeloma-key-statistics">and the USA</a>.<br />
<br />
Carfilzomib is a chirally defined modified tetrapeptidyl epoxide substrate analogue with a molecular weight of 719.9. The molecular formula is C40H57N5O7. (SMILES= O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H(C(=O)N[C@H](C(=O)[C@@]1(OC1)C)CC(C)C)Cc2ccccc2)CC(C)C)CCc3ccccc3)CN4CCOCC4)<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-QzAeheGAGrg/UAvB1khieSI/AAAAAAAAAJs/n7XKtyiSPCM/s1600/carfilzomib.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="171" src="http://2.bp.blogspot.com/-QzAeheGAGrg/UAvB1khieSI/AAAAAAAAAJs/n7XKtyiSPCM/s320/carfilzomib.png" width="320" /></a></div>
<br />
Cmax and AUC following a single <i>intravenous</i> dose of 27 mg/m2 was 4,232 ng/mL and 379 ng.hr/mL, respectively. The mean steady-state volume of distribution of a 20 mg/m2 dose of carfilzomib was 28 L. Carfilzomib was rapidly and extensively metabolised, via peptidases and epoxide hydrolyses - i.e. non-CYP mediated metabolism.&nbsp;After <i>intravenous</i> administration of ≥ 15 mg/m2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour.<br />
<br />
Carfilzomib is a second generation, non-competitive, irreversible proteasome inhibitor. It contains the unusual (for drugs) epoxide group responsible for the irreversible binding to the target. It is differentiated from the first generation proteasome inhibitor bortezomib (boron-based) in this irreversible inhibition mechanism, which is believed to contribute to overcoming bortezomib resistance. Additionally, clinical trials have showed that carfilzomib is associated with fewer incidences of <a href="http://en.wikipedia.org/wiki/Peripheral_neuropathy"> Peripheral Neuropathy (NP)</a> (incidence reported 14% of patients with 1% having Grade 3 NP) in comparison with bortezomib (36% and 24% Grade 3). Epoxides are quite reactive, and can react with many proteins in a biological system.<br />
<br />
<br />
The molecular target for carfilzomib is the 20S catalytic core of the large multi-protein complex - the&nbsp;<a href="http://en.wikipedia.org/wiki/Proteasome">proteasome</a>. Specifically, it binds to the N-terminal threonine-containing active site of the endopeptidase proteasome subunit beta type-7 (Uniprot: <a href="http://www.uniprot.org/uniprot/Q99436">Q99436</a>).<br />
<br />
The amino acid sequence is:<br />
<br />
<pre>&gt;sp|Q99436|PSB7_HUMAN Proteasome subunit beta type-7 OS=Homo sapiens GN=PSMB7 PE=1 SV=1
MAAVSVYAPPVGGFSFDNCRRNAVLEADFAKRGYKLPKVRKTGTTIAGVVYKDGIVLGAD
TRATEGMVVADKNCSKIHFISPNIYCCGAGTAADTDMTTQLISSNLELHSLSTGRLPRVV
TANRMLKQMLFRYQGYIGAALVLGGVDVTGPHLYSIYPHGSTDKLPYVTMGSGSLAAMAV
FEDKFRPDMEEEEAKNLVSEAIAAGIFNDLGSGSNIDLCVISKNKLDFLRPYTVPNKKGT
RLGRYRCEKGTTAVLTEKITPLEIEVLEETVQTMDTS
</pre>
<br />
Prescribing information had be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf">here</a>.<br />
<br />
The licence holder is <a href="http://www.onyx.com/view.cfm/626/onyx-pharmaceuticals-receives-fda-accelerated-approval-of-kyprolis-carfilzomib-for-injection-">Onyx Pharmaceuticals</a> and the product website is <a href="http://www.kyprolis.com/">www.kyprolis.com</a>